Kinsale Capital Group, Inc.
KNSL
$390.64
+3.70%
Kinsale Capital Group, Inc. is a specialty property and casualty insurer operating exclusively in the excess and surplus (E&S) lines market, writing commercial liability and property coverage for small-to-mid-sized accounts across divisions such as allied health, life sciences, professional services, and public entities. The company is a pure-play E&S specialist and a technology-driven, low-cost underwriter that has historically grown premiums far faster than the broader E&S market while running a lean 720-employee operation and a deliberately conservative, short-tail-leaning book. The current investor debate centers on whether Kinsale's premium growth engine is decelerating as the E&S market softens and casualty loss-cost inflation persists, and whether the stock's long stretch of multiple compression has finally gone far enough to make the franchise attractive again. Recent quarterly results showed revenue growth of roughly 16.8% year over year with a sharp sequential margin rebound, but the stock has lagged the market badly over the past year, and sell-side sentiment has drifted toward neutral as analysts wait for evidence that growth can reaccelerate.…
KNSL
Kinsale Capital Group, Inc.
$390.64
Investment Opinion: Should I buy KNSL Today?
Rating: Hold. The core thesis is that Kinsale remains a high-quality franchise with a fortress balance sheet and 25.7% ROE, but the growth deceleration to 16.75% and a consensus target of $346.22 (below the current $365.24) leave limited near-term upside. The analyst consensus rating of 'hold' (mean 3.17) and the stock trading above the average target support a wait-and-see stance until growth reaccelerates.
Supporting evidence includes the valuation at 17.97x trailing and 16.83x forward earnings, a PEG of 0.84, and an EV/EBITDA of 14.0x — all reasonable for a high-ROE insurer. Revenue growth of 16.75% year over year remains healthy, and the Q2 2026 net margin of 32.1% is far above the high-single-digit to low-teens industry norm. Free cash flow TTM of $1.00 billion provides an ~11% FCF yield, and the $100.6 million buyback in Q2 2026 signals management confidence. The implied downside to the average target is -5.2%, while the high target of $405 offers +10.9% upside.
Key risks that could invalidate the thesis include further growth deceleration below 15%, margin compression from casualty inflation, and continued multiple contraction. This Hold would upgrade to Buy if revenue growth reaccelerates above 18% or if the stock pulls back toward the $322-$325 support with stable fundamentals. It would downgrade to Sell if growth falls below 10% or if net margin drops below 20%. On balance, the stock appears fairly valued to slightly undervalued relative to its history, but not yet cheap enough to compensate for the growth uncertainty.
Sign up to view all
KNSL 12-Month Price Forecast
Kinsale is a high-quality franchise undergoing a growth normalization, with the stock's multiple compressed to levels that may already discount much of the deceleration. The Q2 2026 margin rebound to 32.1% net margin and 40.7% operating margin shows earnings power remains strong, but the consensus hold rating and target below the current price suggest limited near-term upside. The key tension is whether 15-17% growth is a trough or a new normal; evidence of reacceleration would likely trigger a re-rating, while continued deceleration could push the stock toward the $264-$290 bear case. I would upgrade to bullish if Q3 2026 revenue growth exceeds 18% with stable margins, and downgrade to bearish if growth falls below 12% or net margin drops below 22%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kinsale Capital Group, Inc.'s 12-month outlook, with a consensus price target around $346.22 and implied upside of -11.4% versus the current price.
Average Target
$346.22
0 analysts
Implied Upside
-11.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$264 - $405
Analyst target range
Nine analysts cover KNSL with a consensus recommendation of "hold" (mean rating 3.17 on a 1-5 scale where higher is more bearish), and the average target price of $346.22 implies roughly -5.2% downside from the current $365.24 — the stock has already rallied past the consensus target, a sign that sentiment may be turning faster than estimates. The distribution leans neutral-to-cautious, with recent actions showing Morgan Stanley at Equal Weight, Wells Fargo at Equal Weight, JP Morgan at Neutral, RBC at Sector Perform, and Cantor at Neutral, while only Truist maintains a Buy. Consensus EPS estimates average $23.06 (range $20.63-$25.69) on average revenue of $1.70 billion, implying the Street expects continued but moderating growth.
The target range of $264 to $405 is wide — a spread of 53% of the average target — signaling high uncertainty about the growth trajectory. The high target of $405 (about +10.9% upside) likely assumes E&S market firming, sustained 15%+ growth, and multiple re-rating toward 18-20x forward earnings, while the low target of $264 (about -27.7% downside) prices in margin compression, competitive share loss, and further multiple contraction. Notably, Wells Fargo downgraded from Overweight to Equal Weight in April 2026, and no firm has upgraded recently — a pattern of fading conviction that, combined with the stock trading above the consensus target, suggests the recent rally may be running ahead of fundamental confirmation and that estimate revisions, not multiple expansion, will need to drive the next leg.
Drowning in data?
Find the real signal!
Bulls vs Bears: KNSL Investment Factors
The bear case currently has stronger evidence: growth has decelerated to 16.75% from 25%+, the stock has badly lagged the market (-16.7% vs. +15.5% one-year), and the consensus target of $346.22 sits below the current price of $365.24. However, the bull case is not without merit — the valuation has compressed to 17.97x trailing earnings from 31.6x in Q1 2025, the PEG of 0.84 suggests undervaluation relative to growth, and the balance sheet is a fortress with 0.115 debt-to-equity and 25.7% ROE. The single most important tension is whether 15-17% growth is the new normal or a trough; if growth stabilizes and reaccelerates, the compressed multiple could re-rate sharply, but if deceleration continues, further multiple contraction is likely. The recent margin rebound (32.1% net margin in Q2 2026) and technical recovery off the September low of $322.75 provide tentative evidence that the worst may be priced in, but confirmation is needed.
Bullish
- Valuation reset to multi-year lows: KNSL trades at 17.97x trailing and 16.83x forward earnings, down from 31.6x in Q1 2025 and 24.7x in Q4 2024, placing it near the bottom of its historical valuation band. The PEG ratio of 0.84 (below 1.0) signals the stock is inexpensive relative to its growth rate, a rare setup for a franchise that historically commanded a 2-3x premium to peers.
- Fortress balance sheet and high returns: Debt-to-equity is just 0.115, ROE is 25.7%, and ROA is 7.56% — exceptional for a P&C insurer. Free cash flow TTM of $1.00 billion against a $9.05 billion market cap implies an ~11% FCF yield, and the company repurchased $100.6 million of stock in Q2 2026 alone, funding growth internally.
- Sharp margin rebound in Q2 2026: Q2 2026 net margin jumped to 32.1% from 24.1% in Q1 2026, with operating margin at 40.7% versus 29.9% prior quarter. EBITDA rose to $223.1 million from $142.8 million sequentially, confirming earnings power remains intact despite quarter-to-quarter catastrophe and reserve timing volatility.
- Growth still mid-teens, not collapsing: Q2 2026 revenue of $548.5 million grew 16.75% year over year and 17.5% sequentially, well above typical P&C industry growth. While below the 25%+ historical pace, this is healthy absolute growth that the market may be mispricing given the stock's 16.7% one-year decline.
Bearish
- Growth deceleration from historical pace: Revenue growth of 16.75% in Q2 2026 is well below the 25%+ rates Kinsale delivered in prior years, consistent with a softening E&S market. The multi-quarter trajectory shows mid-to-high-teens growth becoming the norm, and the stock's historical premium was built on sustained 20%+ compounding.
- Analyst consensus implies downside: Nine analysts have a consensus 'hold' rating (mean 3.17 on a 1-5 scale where higher is more bearish), and the average target price of $346.22 implies -5.2% downside from the current $365.24. The stock has already rallied past the consensus target, suggesting the recent move may be running ahead of fundamental confirmation.
- Severe relative underperformance: KNSL is down 16.7% over the past year versus the S&P 500's +15.5%, a relative strength of -32.2 percentage points. Year-to-date the stock is down 6.9% while the market is up 11.9%, and the 39.4% maximum drawdown underscores how severe the de-rating has been.
- Fading sell-side conviction: Wells Fargo downgraded from Overweight to Equal Weight in April 2026, and no firm has upgraded recently. Recent actions show Morgan Stanley, Wells Fargo, JP Morgan, RBC, and Cantor all at neutral/equal-weight/sector-perform, with only Truist maintaining a Buy — a pattern of fading conviction.
KNSL Technical Analysis
KNSL is in a recovery phase within a broader downtrend: the stock is down 16.7% over the past year and 6.9% year to date, a stark underperformance versus the S&P 500's +15.5% one-year return (relative strength of -32.2 percentage points). At $365.24, the stock sits at roughly 44.5% of its 52-week range of $287.20 to $462.82, meaning it has recovered off the lows but remains far below the highs — a positioning that reflects damaged momentum rather than either a fresh breakout or a falling knife. The 39.4% maximum drawdown underscores how severe the de-rating has been for a name that was once a premium-multiple compounder.
Short-term momentum is improving and diverging positively from the longer-term trend: the stock is up 6.18% over three months and 1.24% over one month, versus a -16.7% one-year change, and it has outperformed the S&P 500 by 3.49 points over three months and 2.46 points over one month. The most recent action is the strongest signal — a 2.17% single-day gain on the latest close to $365.24 from $357.49, extending a rally from the late-September trough near $322.75. Volume of roughly 238,500 shares is modest, and the short ratio of 11.42 days suggests meaningful short interest that could fuel further squeezes if the recovery continues, though it also signals persistent bearish conviction.
Key technical levels are well defined: support sits at the 52-week low of $287.20, with secondary support around the $322-$325 area that held in late September, while resistance lies at the 52-week high of $462.82, with intermediate resistance near the $380-$395 zone where the stock repeatedly stalled in August. A breakout above $395 would signal a genuine trend change and likely force short covering, while a breakdown below $322 would re-test the $287 low and confirm the downtrend. With a beta of 0.871, the stock is roughly 13% less volatile than the market, which is unusual for a high-growth insurer and argues for somewhat larger position sizing per unit of market risk, though the 39.4% drawdown shows idiosyncratic risk remains substantial.
Beta
0.87
0.87x market volatility
Max Drawdown
-39.4%
Largest decline past year
52-Week Range
$287-$463
Price range past year
Annual Return
-13.7%
Cumulative gain past year
| Period | KNSL Return | S&P 500 |
|---|---|---|
| 1m | +11.0% | -1.2% |
| 3m | +11.9% | +3.4% |
| 6m | +13.2% | +7.0% |
| 1y | -13.7% | +14.4% |
| ytd | -0.5% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KNSL Fundamental Analysis
Revenue growth remains solid but is decelerating from the company's historical pace: Q2 2026 revenue was $548.5 million, up 16.75% year over year from $469.8 million in Q2 2025, and up 17.5% sequentially from Q1 2026's $466.7 million. The multi-quarter trajectory shows $423.4 million in Q1 2025, $469.8 million in Q2 2025, $497.5 million in Q3 2025, $483.3 million in Q4 2025, $466.7 million in Q1 2026, and $548.5 million in Q2 2026 — a pattern of mid-to-high-teens growth that is healthy in absolute terms but well below the 25%+ rates Kinsale delivered in prior years, consistent with a softening E&S market. The investment case now hinges on whether 15-17% growth is the new normal or a trough, since the stock's historical premium was built on sustained 20%+ compounding.
Profitability is excellent and margins are rebounding sharply: Q2 2026 net income was $175.9 million on a 32.1% net margin, with gross margin of 57.9% and operating margin of 40.7%, up dramatically from Q1 2026's 24.1% net margin and 29.9% operating margin. The sequential margin expansion reflects both underwriting improvement and a favorable loss environment, and the trailing net margin of 26.9% and operating margin of 33.8% remain far above typical P&C insurance industry levels in the high single digits to low teens. EBITDA of $223.1 million in Q2 2026 (40.7% EBITDA margin) versus $142.8 million in Q1 2026 confirms the earnings power is intact and volatile quarter-to-quarter largely on catastrophe and reserve timing.
Financial health is a standout strength: debt-to-equity is just 0.115, the current ratio is 0.84 (typical for insurers where reserves and investments dominate the balance sheet), and free cash flow TTM is $1.00 billion against a $9.05 billion market cap — a roughly 11% FCF yield. ROE of 25.7% and ROA of 7.56% are exceptional for an insurer, and quarterly operating cash flow has been consistently strong at $241.9 million in Q2 2026, $248.9 million in Q1 2026, and $241.4 million in Q4 2025. The company funds growth internally, returns capital via buybacks ($100.6 million repurchased in Q2 2026 alone) and a token dividend yielding 0.17%, and carries negligible leverage risk — a fortress balance sheet that provides downside protection.
Quarterly Revenue
$548519000.0B
2026-06
Revenue YoY Growth
+16.8%
YoY Comparison
Gross Margin
57.9%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KNSL Overvalued?
Because Kinsale is solidly profitable (Q2 2026 net income of $175.9 million), the PE ratio is the appropriate primary metric: the stock trades at 17.97x trailing earnings and 16.83x forward earnings, an unusually narrow gap that implies the market expects only modest earnings growth — a stark contrast to the premium multiples Kinsale historically commanded. The PEG ratio of 0.84 (below 1.0) suggests the stock is inexpensive relative to its growth rate, and the EV/EBITDA of 14.0x and EV/Sales of 4.09x are reasonable for a high-ROE specialty insurer.
Against the broader P&C insurance sector, where peers typically trade in the 10-15x PE range, Kinsale's 17.97x trailing PE represents a modest premium of roughly 20-50% — far narrower than the 2-3x premium it historically commanded. That compression is arguably justified by decelerating growth (16.75% versus historical 25%+) but may understate the value of a 25.7% ROE and 32% net margin franchise; the PS ratio of 4.83x and PB ratio of 4.62x are elevated relative to traditional insurers but reflect the asset-light, high-return underwriting model. On balance, the valuation looks reasonable-to-attractive for a quality compounder, with the PEG below 1.0 the clearest signal of undervaluation.
Historical context is striking: Kinsale's PE ratio has collapsed from 31.6x in Q1 2025 and 24.7x in Q4 2024 to 17.97x today, while the PS ratio has fallen from 26.6x in Q1 2025 to 4.83x and the PB ratio from 7.12x to 4.62x — the stock is near the bottom of its multi-year valuation band. This de-rating reflects both multiple compression and strong earnings growth, and while it could signal fundamental deterioration (slower growth, E&S market softening), it also creates a value opportunity if growth stabilizes. The market is no longer pricing in optimistic expectations, which limits downside but also means a re-rating requires proof of reaccelerating growth.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings volatility and growth dependence. Quarterly net margins have swung from 21.1% in Q1 2025 to 32.1% in Q2 2026, with Q1 2026 at 24.1%, reflecting catastrophe and reserve timing that makes earnings less predictable than the trailing 26.9% net margin suggests. Revenue growth of 16.75% is now the engine supporting a 17.97x PE, and any deceleration below 15% would pressure the valuation. The current ratio of 0.84 is typical for insurers but leaves little liquidity cushion, and while debt-to-equity of 0.115 is low, the company's growth is concentrated in a single E&S segment exposed to casualty loss-cost inflation.
Market and competitive risks include valuation compression and E&S market softening. The stock's PE has collapsed from 31.6x in Q1 2025 to 17.97x, and further de-rating is possible if growth slows; the 39.4% maximum drawdown shows how severe multiple compression can be. Kinsale faces competition from larger carriers entering E&S lines, and a softening market could pressure premium rates. The beta of 0.871 offers some downside protection versus the market, but the stock's -32.2 percentage point relative strength over one year shows it is not immune to sector rotation. Recent news flow is sparse, but the Wells Fargo downgrade in April 2026 highlights fading conviction.
The worst-case scenario is a continued E&S market softening combined with casualty loss-cost inflation, leading to growth decelerating below 10% and margins compressing toward industry norms. In that scenario, the stock could retest its 52-week low of $287.20, implying -21.4% downside from $365.24, or fall to the analyst low target of $264, implying -27.7% downside. A more severe outcome — multiple contraction to 14x forward earnings on lower estimates — could push the stock toward $250, a -31.5% decline. The 39.4% maximum drawdown is a reminder that such moves are within historical experience.
FAQ
The most severe risk is growth deceleration: revenue growth has already slowed to 16.75% from 25%+, and a further decline below 10% could trigger multiple contraction toward 14x earnings, implying a price near $264 (-27.7%). Second is margin compression from casualty loss-cost inflation, as quarterly net margins have swung from 21.1% to 32.1%, and a drop below 20% would undermine the earnings base. Third is competitive pressure in the E&S market, where larger carriers entering the space could pressure premium rates and share. Fourth is valuation risk: despite the compression, the stock still trades at a premium to peers, and the 39.4% maximum drawdown shows how quickly sentiment can reverse. The beta of 0.871 offers some market protection, but idiosyncratic risk remains substantial.
The 12-month forecast has three scenarios: a base case (50% probability) of $340-$370, assuming growth stabilizes in the mid-teens and margins hold in the high-20s to low-30s, centered on the analyst average target of $346.22; a bull case (25% probability) of $405-$430, driven by E&S market firming and revenue growth reaccelerating above 18%; and a bear case (25% probability) of $264-$290, if growth decelerates below 10% and margins compress. The base case is most likely, with the key assumption being that Q2 2026's 16.75% growth represents a trough rather than a continued decline. The wide analyst target range of $264-$405 (53% spread) reflects genuine uncertainty, and the stock's current price of $365.24 is above the average target, suggesting the market has already priced in some recovery.
KNSL appears fairly valued to slightly undervalued relative to its own history but at a modest premium to peers. The trailing PE of 17.97x is down from 31.6x in Q1 2025 and 24.7x in Q4 2024, placing it near the bottom of its multi-year band, while the PEG of 0.84 (below 1.0) signals undervaluation relative to growth. Against P&C peers trading at 10-15x earnings, KNSL's 17.97x represents a 20-50% premium — far narrower than the 2-3x premium it historically commanded. The market appears to be pricing in modest earnings growth (forward PE of 16.83x implies only ~7% earnings growth), which may understate the value of a 25.7% ROE and 32.1% net margin franchise. A re-rating toward 20x forward earnings would imply a price near $460, close to the 52-week high.
From a risk/reward perspective, KNSL offers a mixed picture: the stock trades at 17.97x trailing earnings with a PEG of 0.84, suggesting it is inexpensive relative to growth, but the consensus target of $346.22 implies -5.2% downside from $365.24. The biggest downside risk is a retest of the 52-week low of $287.20 (-21.4%) if growth decelerates further, while the high target of $405 offers +10.9% upside. For long-term investors with a 2-3 year horizon, the fortress balance sheet (debt-to-equity 0.115), 25.7% ROE, and ~11% FCF yield make it a reasonable accumulation candidate on pullbacks toward $322-$325 support. For short-term traders, the stock is above consensus target and facing resistance at $380-$395, so waiting for a breakout or a better entry point is prudent.
KNSL is better suited for long-term investment (minimum 2-3 years) than short-term trading. The company is in a growth normalization phase with a 25.7% ROE, 0.115 debt-to-equity, and ~11% FCF yield that support compounding over time, but near-term earnings visibility is limited by catastrophe and reserve timing volatility (net margins ranged from 21.1% to 32.1% over five quarters). The beta of 0.871 is lower than the market, but the 39.4% maximum drawdown and 11.42-day short ratio indicate meaningful idiosyncratic volatility that could shake out short-term holders. The token dividend yield of 0.17% provides negligible income, so returns depend on capital appreciation. A suggested minimum holding period of 2-3 years allows time for the E&S cycle to turn and for the compressed multiple to re-rate if growth stabilizes.